Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

Table 1

Characteristics of the included studies.

Reference	Year	Disease	Sample size (E/C)	Sex (M/F)		Age(years) (E/C)	Interventions		Follow-up time	Outcome measures	Criteria for efficacy
				E	C		E	C
Dang et al. [15]	2014	GC (advanced)	100(50/50)	Unknown		61.06 ± 4.21/60.21 ± 4.62	Rg3 +C	DDP + placebo	8 months	①②④⑤	WHO
Liu et al. [16]	2017	GC (IIIA: 15, IIIB: 52, IIIC: 22)	89(52/37)	29/23	20/17	45.1 ± 8.5/44.8 ± 9.3	Rg3 +C	FOLFOX4	6 months	①②⑤	RECIST
Wei et al. [17]	2015	GC (III-IV)	200(100/100)	68/32	70/30	18–75(48.5 ± 6.7)/19–74(46.5 ± 5.7)	Rg3 +C	Tegafur + DDP	5 years	①②⑤	RECIST
Zhou et al. [18]	2013	GC (advanced)	80(40/40)	Unknown		44–73(61)/43–72 (60)(median age)	Rg3 +C	PTX	4 years	①③⑤	WHO
Bian et al. [19]	2014	CRC (advanced)	61(30/31)	18/12	17/14	54.6 ± 9.6/57.1 ± 7.4	Rg3 +C	XELOX	2 years	⑤	RECIST
Gai et al. [20]	2010	CRC (advanced)	49(25/24)	28/21		35–75	Rg3 +C	XELOX	9 weeks	①②④⑤	WHO
Liu et al. [21]	2015	CRC III (77%), IV (23%)	113(63/50)	53/60		18–80 (median age 55)	Rg3 +C	Fluorouracil + placebo	14 months	①②④⑤	WHO
Lou [22]	2010	CRC (II-III)	94(47/47)	Unknown		41–75	Rg3 +C	FOLFOX6	2 months	⑤	RECIST
Zeng et al. [23]	2009	CRC (IV)	67(35/32)	25/10	22/11	51–69	Rg3 +C	FOLFOX4	2 months	①②④⑤	WHO
Huang et al. [24]	2009	EC (IV)	60(30/30)	17/13	18/12	45–75(54)/42–74 (52)(median age)	Rg3 +C	GP(GEM + DDP)	1 year	①②③④⑤	WHO
Wang [25]	2010	EC (advanced)	70(35/35)	46/24		32–78 (median age 56)	Rg3 +C	NP(NVB + DDP)	6 weeks	①②④⑤	WHO
Zhou [26]	2015	EC (T3-T4a)	207(99/108)	65/34	70/38	48–76(61.6 ± 7.6)/50–79(63.5 ± 8.4) (average age)	Rg3 +C	TP(PTX + DDP)	3 years	①②③⑤	WHO
Liu et al. [27]	2015	LC (advanced)	64(32/32)	18/14	17/15	52.13 ± 10.25/53.27 ± 11.59	Rg3 +C	TACE + lipiodol + pirarubicin	3 months	①②⑤	GPCRNCM
Ouyang et al. [28]	2009	LC (II: 9, III: 39, IV: 13)	61(30/31)	25/5	23/8	21–72 (median age 50)	Rg3 +C	TACE + lipiodol	2 years	①②③④⑤	GPCRNCM
Zhao et al. [29]	2009	LC (advanced)	40(20/20)	14/6	16/4	59.5 ± 11.6/62.3 ± 10.8	Rg3 +C	TACE + GP + ML	2 years	①②③④⑤	GPCRNCM
Chen et al. [30]	2012	LC (advanced)	60(30/30)	Unknown		Unknown	Rg3 +C	TACE + Fluorouracil + DDP + ML	3 years	②③④⑤	WHO
Wang et al. [31]	2014	LC (advanced)	48(24/24)	29/19		52.13 ± 3.65	Rg3 +C	TACE + mitomycin + adriamycin+	6 months	①②⑤	Unknown
Li [32]	2018	PC (III: 59, IV: 9)	68(34/34)	21/13	20/14	52.2 ± 3.8/52.3 ± 3.9	Rg3 +C	GEM	4 months	⑤	Unknown

Note. E: experimental group; C: control group; Rg3: Rg3 20 mg po.Bid; PTX: paclitaxel; DDP: cisplatin; XELOX: oxaliplatin + capecitabine; FOLFOX4/FOLFOX6: oxaliplatin + calcium folinate + fluorouracil; GP (GEM + DDP): gemcitabine + cisplatin; TP (PTX + DDP): paclitaxel + cisplatin; NP (NVB + DDP): vinorelbine + cisplatin; TACE: transcatheter arterial chemoembolization; ML: mitomycin + lipiodol; WHO: World Health Organization; RECIST: the response evaluation criteria in solid tumors; GPCRNCM: Guiding Principles for Clinical Research of New Chinese Medicines; ① ORR; ② DCR; ③ SR; ④ KPS; ⑤ side effects.